BNP PARIBAS ASSET MANAGEMENT Holding S.A. Has $2.56 Million Holdings in DaVita Inc. $DVA

BNP PARIBAS ASSET MANAGEMENT Holding S.A. trimmed its position in shares of DaVita Inc. (NYSE:DVA) by 77.2% during the third quarter, Holdings Channel.com reports. The firm owned 19,801 shares of the company’s stock after selling 67,046 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A.’s holdings in DaVita were worth $2,563,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of the business. NewEdge Advisors LLC raised its holdings in DaVita by 20.8% during the first quarter. NewEdge Advisors LLC now owns 511 shares of the company’s stock worth $78,000 after buying an additional 88 shares during the last quarter. Goldman Sachs Group Inc. raised its holdings in shares of DaVita by 19.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 179,140 shares of the company’s stock worth $27,403,000 after acquiring an additional 28,739 shares during the last quarter. Sequoia Financial Advisors LLC lifted its position in DaVita by 7.6% in the 2nd quarter. Sequoia Financial Advisors LLC now owns 2,018 shares of the company’s stock valued at $287,000 after acquiring an additional 143 shares in the last quarter. DekaBank Deutsche Girozentrale boosted its stake in DaVita by 8.4% during the 2nd quarter. DekaBank Deutsche Girozentrale now owns 14,013 shares of the company’s stock valued at $1,991,000 after purchasing an additional 1,084 shares during the last quarter. Finally, Ethic Inc. increased its holdings in DaVita by 36.9% during the 2nd quarter. Ethic Inc. now owns 3,091 shares of the company’s stock worth $438,000 after purchasing an additional 833 shares in the last quarter. Institutional investors and hedge funds own 90.12% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on DVA. UBS Group raised their target price on DaVita from $186.00 to $190.00 and gave the company a “buy” rating in a report on Wednesday, February 4th. Weiss Ratings restated a “hold (c)” rating on shares of DaVita in a research note on Monday, December 29th. TD Cowen reaffirmed a “hold” rating on shares of DaVita in a report on Tuesday, February 3rd. Zacks Research upgraded shares of DaVita from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, February 4th. Finally, Barclays raised their price target on shares of DaVita from $143.00 to $158.00 and gave the company an “equal weight” rating in a research report on Tuesday, February 3rd. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $160.50.

DaVita Price Performance

NYSE DVA opened at $147.12 on Friday. The business’s fifty day moving average is $120.13 and its 200-day moving average is $125.20. The stock has a market capitalization of $9.83 billion, a price-to-earnings ratio of 14.85, a PEG ratio of 0.52 and a beta of 0.99. DaVita Inc. has a one year low of $101.00 and a one year high of $157.12.

DaVita (NYSE:DVA) last posted its quarterly earnings data on Monday, February 2nd. The company reported $3.40 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.24 by $0.16. The business had revenue of $3.62 billion during the quarter, compared to the consensus estimate of $3.51 billion. DaVita had a net margin of 5.47% and a negative return on equity of 413.18%. The firm’s quarterly revenue was up 9.9% compared to the same quarter last year. During the same quarter last year, the company posted $2.24 earnings per share. DaVita has set its FY 2026 guidance at 13.600-15.00 EPS. Research analysts expect that DaVita Inc. will post 10.76 EPS for the current fiscal year.

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.